Pictet Asset Management Holding SA Sells 3,261 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Pictet Asset Management Holding SA lowered its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,089 shares of the company’s stock after selling 3,261 shares during the quarter. Pictet Asset Management Holding SA owned 0.39% of Krystal Biotech worth $17,560,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new position in Krystal Biotech during the 3rd quarter worth $40,000. Avanza Fonder AB purchased a new position in Krystal Biotech during the fourth quarter worth about $119,000. KBC Group NV grew its position in Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock worth $147,000 after purchasing an additional 297 shares in the last quarter. Blue Trust Inc. increased its stake in Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock valued at $159,000 after buying an additional 433 shares during the last quarter. Finally, US Bancorp DE lifted its position in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after buying an additional 82 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Down 3.2 %

KRYS opened at $174.58 on Wednesday. The company has a market capitalization of $5.03 billion, a price-to-earnings ratio of 58.39 and a beta of 0.87. The firm has a 50-day moving average price of $171.92 and a 200-day moving average price of $173.26. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same quarter in the previous year, the firm posted $0.30 EPS. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on KRYS. Jefferies Financial Group initiated coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price for the company. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup increased their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).